表紙
市場調査レポート

アジア太平洋地域における2型糖尿病治療 〜2021年:新たな治療法の導入拡大と治療人口の増加が市場の成長を促進

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

発行 GBI Research 商品コード 351834
出版日 ページ情報 英文 166 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
アジア太平洋地域における2型糖尿病治療 〜2021年:新たな治療法の導入拡大と治療人口の増加が市場の成長を促進 Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
出版日: 2016年01月01日 ページ情報: 英文 166 Pages
概要

2型糖尿病の治療は過去10年で劇的に変化し、特に新規の治療法が多く用いられるようになりました。2014〜2021年にかけ、アジア太平洋地域における2型糖尿病治療市場はCAGR7.7%で拡大し、60億7,000万米ドルから102億米ドルに成長すると見込まれています。

当レポートでは、アジア太平洋地域における2型糖尿病治療市場について調査し、市場の現状と既存の治療薬の競合力、パイプライン動向、2006年以降の治験分析、2021年までの市場成長見通し、および参入企業の競合動向などをまとめています。

第1章 目次

第2章 イントロダクション

  • 疾患の概要
  • 分類
  • 徴候
  • 病因
  • 病態生理学
  • 疫学
  • 予後
  • 併存疾患および合併症
  • 診断
  • 治療効果の評価
  • 治療
  • 治療セグメント

第3章 上市済み製品

  • 概要
  • Biguanide
  • Sulfonylurea
  • Thiazolidinedione
  • GLP-1受容体作動薬
  • DPP-4阻害剤
  • SGLT-2阻害剤
  • インスリン治療
  • ヒートマップ

第4章 パイプライン

  • 概要
  • 開発段階、分子タイプ、プログラムタイプ別パイプライン分布
  • 分子標的別パイプライン分布
  • 治験動向
    • 失敗率
    • 期間
    • 規模
    • 指標分析
  • 有望なパイプライン分子
  • ヒートマップ

第5章 2021年までの市場予測

  • 地域別市場
  • アジア太平洋地域
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 市場促進因子と障壁

第6章 戦略的統合

  • ライセンシング契約
  • 共同開発契約

第7章 付録

図表

目次
Product Code: GBIHC380MR

Executive Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

  • The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
  • What are the competitive advantages of the existing novel drugs?
  • With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the T2DM market?
  • Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
  • Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the four assessed Asia-Pacific markets?
  • Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.
  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Which patent expirations will have the most significant impact on the market?

Reasons to buy

This report will enable you to -

  • Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan.
  • Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Overview
  • 2.2. Classification
  • 2.3. Symptoms
  • 2.4. Etiology
  • 2.5. Pathophysiology
  • 2.6. Epidemiology
  • 2.7. Prognosis
  • 2.8. Co-morbidities and Complications
  • 2.9. Diagnosis
  • 2.10. Assessing Treatment Effectiveness
  • 2.11. Treatment
    • 2.11.1. Non-insulin T2DM Therapies
    • 2.11.2. Insulin T2DM Therapies
  • 2.12. Treatment Segments
    • 2.12.1. Non-insulin therapies
    • 2.12.2. Insulin Therapies

3. Marketed Products

  • 3.1. Overview
  • 3.2. Biguanides
    • 3.2.1. Metformin
  • 3.3. Sulfonylureas
  • 3.4. Thiazolidinediones
    • 3.4.1. Pioglitazone
  • 3.5. GLP-1 receptor agonists
    • 3.5.1. Byetta (exenatide)
    • 3.5.2. Bydureon (exenatide)
    • 3.5.3. Victoza (liraglutide)
    • 3.5.4. Lyxumia (lixisenatide)
    • 3.5.5. Tanzeum (albiglutide)
    • 3.5.6. Trulicity (dulaglutide)
  • 3.6. DPP-4 Inhibitors
    • 3.6.1. Januvia/Glactiv (sitagliptin)
    • 3.6.2. Galvus (vildagliptin)
    • 3.6.3. Onglyza (saxagliptin)
    • 3.6.4. Trazenta (linagliptin)
    • 3.6.5. Zafatek (trelagliptin succinate)
    • 3.6.6. Marizev (omarigliptin)
  • 3.7. SGLT-2 Inhibitors
    • 3.7.1. Forxiga (dapagliflozin)
    • 3.7.2. Invokana (canagliflozin)
    • 3.7.3. Jardiance (empagliflozin)
  • 3.8. Insulin Therapies
    • 3.8.1. Lantus (insulin glargine)
    • 3.8.2. Levemir (insulin detemir)
    • 3.8.3. Tresiba (insulin degludec)
    • 3.8.4. Toujeo/ Lantus XR (insulin glargine)
  • 3.9. Marketed Products Heat Maps

4. Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Distribution by Stage of Development, Molecule Type and Program Type
  • 4.3. Pipeline Distribution by Molecular Target
  • 4.4. Clinical Trial Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Clinical Trial Metrics Analysis
  • 4.5. Promising Pipeline Molecules
    • 4.5.1. NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
    • 4.5.2. ITCA 650 - Intarcia Therapeutics
    • 4.5.3. Ertugliflozin - Pfizer
  • 4.6. Pipeline Products Heat Map

5. Market Forecast to 2021

  • 5.1. Geographical Markets
  • 5.2. Asia-Pacific Markets
  • 5.3. China
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. India
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Australia
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Japan
    • 5.6.1. Treatment Usage Patterns
    • 5.6.2. Annual Cost of Therapy
    • 5.6.3. Market Size
  • 5.7. Drivers and Barriers for the T2DM Therapeutics Market
    • 5.7.1. Drivers
    • 5.7.2. Barriers

6. Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. AbbVie Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology
    • 6.1.2. Janssen Collaborates with Halozyme Therapeutics to Bank on its ENHANZE Technology
    • 6.1.3. Emisphere Signs Licensing Agreement with Novo Nordisk to Develop Oral Formulations Targeting Metabolic Indications
    • 6.1.4. Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN Products
  • 6.2. Co-development Deals
    • 6.2.1. Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 (DUROS delivery exenatide)
    • 6.2.2. Merck Enters into Co-Development Agreement with Pfizer for ertugliflozin
    • 6.2.3. AstraZeneca Enters into Research Agreement with Inserm
    • 6.2.4. Intarcia Therapeutics Enters into Co-Development Agreement with Numab
    • 6.2.5. AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Asia-Pacific
    • 7.2.2. China
    • 7.2.3. India
    • 7.2.4. Australia
    • 7.2.5. Japan
  • 7.3. References
  • 7.4. Abbreviations
  • 7.5. Research Methodology
    • 7.5.1. Secondary Research
    • 7.5.2. Marketed Product Profiles
    • 7.5.3. Late-Stage Pipeline Candidates
    • 7.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.5.5. Forecasting Model
    • 7.5.6. Deals Data Analysis
  • 7.6. Contact Us
  • 7.7. Disclaimer

List of Tables

  • Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy
  • Table 2: T2DM Therapeutics Market, Global, Breakdown of Multiple Molecular Targets, 2015
  • Table 3: T2DM Therapeutics Market, Global, Breakdown of ''Other'' Molecular Targets, 2015
  • Table 4: T2DM Therapeutics, Global, All Pipeline Products, Discovery Phase, 2015
  • Table 5: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2015
  • Table 6: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2015
  • Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase I, 2015
  • Table 8: T2DM Therapeutics, Global, All Pipeline Products, Phase II, 2015
  • Table 9: T2DM Therapeutics, Global, All Pipeline Products, Phase III, 2015
  • Table 10: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
  • Table 11: T2DM Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 12: T2DM Therapeutics Market, China, Market Forecast, 2014-2021
  • Table 13: T2DM Therapeutics Market, India, Market Forecast, 2014-2021
  • Table 14: T2DM Therapeutics Market, Australia, Market Forecast, 2014-2021
  • Table 15: T2DM Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015
  • Figure 2: T2DM Therapeutics Market, Global, Heat Map for Marketed Products, 2015 (continued)
  • Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2015
  • Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2015
  • Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of GPCR Molecular Targets, 2015
  • Figure 6: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Protein Kinase Molecular Targets, 2015
  • Figure 7: T2DM Therapeutics Market, Global, Clinical Trial Failure Rates and Reasons for Failure, 2006-2015
  • Figure 8: T2DM Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015
  • Figure 9: T2DM Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2015
  • Figure 10: T2DM Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, (months), 2006-2015
  • Figure 11: T2DM Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target, (months), 2006-2015
  • Figure 12: T2DM Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type, (participants), 2006-2015
  • Figure 13: T2DM Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecular Target, (participants), 2006-2015
  • Figure 14: T2DM Mellitus Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Stage of Development and Molecule Type, (participants), 2006-2015
  • Figure 15: T2DM Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Stage of Development and Molecular Target, (participants), 2006-2015
  • Figure 16: T2DM Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 17: T2DM Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 18: T2DM Therapeutics Market, Asia-Pacific, Semaglutide Products Forecast ($m), 2017-2021
  • Figure 19: T2DM Therapeutics Market, Asia-Pacific, ITCA-650 (exenatide) Products Forecast ($m), 2017-2021
  • Figure 20: T2DM Therapeutics Market, Asia-Pacific, Ertugliflozin Products Forecast ($m), 2018-2021
  • Figure 21: T2DM Market, Global, Heat Map for Pipeline Products, 2015
  • Figure 22: T2DM Therapeutics Market, Asia-Pacific, Treatment Usage Patterns, 2014-2021
  • Figure 23: T2DM Therapeutics Market, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 24: T2DM Therapeutics Market, China, Treatment Usage Patterns, 2014-2021
  • Figure 25: T2DM Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 26: T2DM Therapeutics Market, China, Market Size ($bn), 2014-2021
  • Figure 27: T2DM Therapeutics Market, India, Treatment Usage Patterns, 2014-2021
  • Figure 28: T2DM Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 29: T2DM Therapeutics Market, India, Market Size ($bn), 2014-2021
  • Figure 30: T2DM Therapeutics Market, Australia, Treatment Usage Patterns, 2014-2021
  • Figure 31: T2DM Therapeutics Market, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 32: T2DM Therapeutics Market, Australia, Market Size ($bn), 2014-2021
  • Figure 33: T2DM Therapeutics Market, Japan, Treatment Usage Patterns, 2014-2021
  • Figure 34: T2DM Therapeutics Market, Japan, Annual Cost of Therapy (ACoT) ($), 2014-2021
  • Figure 35: T2DM Therapeutics Market, Japan, Market Size ($bn), 2014-2021
  • Figure 36: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006-2015
  • Figure 37: T2DM Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 38: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
  • Figure 39: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2015
  • Figure 40: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-2015
  • Figure 41: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
  • Figure 42: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-2015
  • Figure 43: T2DM Therapeutics Market, Global, Co-Development Deals by Region, 2006-2015
  • Figure 44: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2014
  • Figure 45: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2015
  • Figure 46: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-2015
  • Figure 47: T2DM Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
Back to Top